1.	Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-1207, 2012-002317-18, NCT01646554
2.	Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AFLIBC06097, 2011-005724-17, U1111-1125-8949, NCT01571284
3.	Colorectal Cancer Metastatic Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AFLIBL06266, 2012-000048-89, U1111-1128-9325, NCT01670721
4.	A Study of Aflibercept Versus Placebo With FOLFIRI in Asian Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC11338, U1111-1115-7227, NCT01661270
5.	Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Pro00037688, NCT01661972
6.	Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00559, E4805, ECOG-E4805, CDR0000489069, U10CA021115, NCT00357760
7.	Aflibercept in Treating Patients With Myelodysplastic Syndromes Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00180, PHII-73, N01CM62209, CDR0000558101, CCC-PHII-73, 7518, NCT00509249
8.	Aldesleukin With or Without Aflibercept in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: Over 16 Sponsor: NCI Protocol IDs: NCI-2011-02498, PHII-107, N01CM00038, CHNMC-PHII-107, 8628, NCT01258855
9.	Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OSU 11182, NCI-2012-01167, NCT01652196
10.	Adjuvant Aflibercept for Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG C261, NCT01669720
11.	FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-401, NCT01747551
12.	5-FU, Aflibercept, and RT for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SCRI GI 168, NCT01749956
13.	Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-456, NCT01782443
14.	OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: VELVET C12-1, 2012-003521-25, NCT01802684
15.	Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: R910-ST-1114, NCT01688960